Skip to main content
Advertisement
  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Genetics
    • Neuroimmunology & Neuroinflammation
    • Education
  • Online Sections
    • Neurology Video Journal Club
    • Inclusion, Diversity, Equity, Anti-racism, & Social Justice (IDEAS)
    • Innovations in Care Delivery
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • COVID-19
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Null Hypothesis
    • Patient Pages
    • Topics A-Z
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center

Advanced Search

Main menu

  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Genetics
    • Neuroimmunology & Neuroinflammation
    • Education
  • Online Sections
    • Neurology Video Journal Club
    • Inclusion, Diversity, Equity, Anti-racism, & Social Justice (IDEAS)
    • Innovations in Care Delivery
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • COVID-19
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Null Hypothesis
    • Patient Pages
    • Topics A-Z
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Residents & Fellows

User menu

  • Subscribe
  • My Alerts
  • Log in

Search

  • Advanced search
Neurology
Home
The most widely read and highly cited peer-reviewed neurology journal
  • Subscribe
  • My Alerts
  • Log in
Site Logo
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Residents & Fellows

Share

February 12, 2013; 80 (7 Supplement) March 21,2013

Vitamin D Status as a Risk Factor for Cerebral Demyelination in X-Linked Adrenoleukdystrophy (S60.005)

Keith Van Haren, Ellen Mowry, Gerald Raymond, Ann Moser, Lawrence Steinman
First published February 8, 2016,
Keith Van Haren
1 Stanford University/Lucile Packard Children's Hospital Palo Alto CA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ellen Mowry
2 Johns Hopkins University Baltimore MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gerald Raymond
3 Kennedy Krieger Institute/Johns Hopkins University Baltimore MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ann Moser
4 Kennedy Krieger Institute/Johns Hopkins University Baltimore MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lawrence Steinman
5 Stanford University Stanford CA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Citation
Vitamin D Status as a Risk Factor for Cerebral Demyelination in X-Linked Adrenoleukdystrophy (S60.005)
Keith Van Haren, Ellen Mowry, Gerald Raymond, Ann Moser, Lawrence Steinman
Neurology Feb 2013, 80 (7 Supplement) S60.005;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Permissions

Make Comment

See Comments

Downloads
0

Share

  • Article
  • Info & Disclosures
Loading

Abstract

OBJECTIVE: To determine whether low vitamin levels are associated with an increased risk of cerebral demyelination in boys with X-linked adrenoleukodystrophy (ALD).

BACKGROUND: ALD is a monogenetic peroxisomal disorder (ABCD1 gene; 1:17,000) characterized by elevated levels of very long chain fatty acids. Approximately 40% of ALD boys develop inflammatory cerebral demyelination between 4 and 12 years of age. The risk factors associated with cerebral demyelination are unknown.

DESIGN/METHODS: Plasma samples were collected prospectively and biobanked at -80C as part of a single center longitudinal cohort. Patients were selected for this study based on the availability of plasma from at least two timepoints prior to clinical endpoint. The clinical endpoints were defined as 1) the diagnosis of cerebral demyelination or 2) the end of clinical follow-up with no demyelination. ALD boys who developed cerebral demyelination (n=8) were age-matched with ALD boys (n=8) who had no cerebral demyelination. 25-OH vitamin D levels were measured via LCMSMS by a blinded third party (Heartland Assays, Inc). We used a previously described algorithm to adjust 25-OH levels for date of blood draw. We used Mann-Whitney test (Prism software)to directly compare the average deseasonalized 25-OH levels between the two groups. We used a generalized estimating equation (STATA software) to estimate the odds ratio of developing cerebral demyelination based on the unadjusted 25-OH level.

RESULTS: We found that the average deseasonalized 25-OH level was significantly lower in the ALD boys who later developed cerebral demyelination (p=0.05). We also found that each 10ng/ml increase in unadjusted vitamin D is associated with an odds ratio of cerebral demyelination of 0.26 (95%CI 0.05,1.35), p=0.109.

CONCLUSIONS: Low plasma vitamin D levels may be a risk factor for cerebral demyelination in ALD boys. If confirmed, these findings would provide a rationale for a clinical trial of vitamin D to prevent cerebral demyelination in ALD boys.

Supported by: Scientific Award from the Child Neurology Foundation; Sprague-McHugh Family Award from the Lucile Packard Foundation; NIH Loan Repayment Program.

Disclosure: Dr. Van Haren has nothing to disclose. Dr. Mowry has received research support from Teva Neuroscience. Dr. Raymond has received personal compensation for activities with from Bluebird Bio as a speaker. Dr. Raymond has received research support from Bluebird Bio. Dr. Moser has nothing to disclose. Dr. Steinman has received personal compensation for activies with Biogen-Idec, Teva, MedImmune, Sanofi, and Bayer.

Thursday, March 21 2013, 2:00 pm-3:30 pm

  • Copyright © 2013 by AAN Enterprises, Inc.

Disputes & Debates: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
  • Article
  • Info & Disclosures
Advertisement

Related Articles

  • No related articles found.

Alert Me

  • Alert me when eletters are published
Neurology: 99 (6)

Articles

  • Ahead of Print
  • Current Issue
  • Past Issues
  • Popular Articles
  • Translations

About

  • About the Journals
  • Ethics Policies
  • Editors & Editorial Board
  • Contact Us
  • Advertise

Submit

  • Author Center
  • Submit a Manuscript
  • Information for Reviewers
  • AAN Guidelines
  • Permissions

Subscribers

  • Subscribe
  • Activate a Subscription
  • Sign up for eAlerts
  • RSS Feed
Site Logo
  • Visit neurology Template on Facebook
  • Follow neurology Template on Twitter
  • Visit Neurology on YouTube
  • Neurology
  • Neurology: Clinical Practice
  • Neurology: Genetics
  • Neurology: Neuroimmunology & Neuroinflammation
  • Neurology: Education
  • AAN.com
  • AANnews
  • Continuum
  • Brain & Life
  • Neurology Today

Wolters Kluwer Logo

Neurology | Print ISSN:0028-3878
Online ISSN:1526-632X

© 2022 American Academy of Neurology

  • Privacy Policy
  • Feedback
  • Advertise